Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
2.48 EUR | +1.64% | -8.15% | +2.90% |
04-22 | BioXcel Therapeutics to Launch At-Home Trial of Potential Bipolar, Schizophrenia Agitation Treatment | MT |
04-11 | Gerresheimer shares down on outlook, but key contracts confirmed | RE |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+2.90% | 38.68M | |
+9.92% | 7.42B | |
-13.33% | 291M | |
-.--% | 62.2M |
- Stock Market
- Equities
- ADMIN Stock
- News Administer Oyj
- PharmaTher and Vitruvias in Collaboration Agreement for Commercialization of Ketarx in the U.S.